Wealth Enhancement Advisory Services LLC Has $66.21 Million Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Wealth Enhancement Advisory Services LLC boosted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 127,272 shares of the medical research company’s stock after buying an additional 1,556 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Thermo Fisher Scientific were worth $66,211,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Semus Wealth Partners LLC lifted its stake in shares of Thermo Fisher Scientific by 4.0% in the 4th quarter. Semus Wealth Partners LLC now owns 471 shares of the medical research company’s stock valued at $245,000 after purchasing an additional 18 shares during the period. Evernest Financial Advisors LLC lifted its stake in shares of Thermo Fisher Scientific by 4.0% in the 4th quarter. Evernest Financial Advisors LLC now owns 521 shares of the medical research company’s stock valued at $271,000 after purchasing an additional 20 shares during the period. Proactive Wealth Strategies LLC lifted its stake in shares of Thermo Fisher Scientific by 2.7% in the 4th quarter. Proactive Wealth Strategies LLC now owns 753 shares of the medical research company’s stock valued at $392,000 after purchasing an additional 20 shares during the period. Cassaday & Co Wealth Management LLC lifted its stake in shares of Thermo Fisher Scientific by 0.9% in the 4th quarter. Cassaday & Co Wealth Management LLC now owns 2,286 shares of the medical research company’s stock valued at $1,189,000 after purchasing an additional 20 shares during the period. Finally, Callan Capital LLC lifted its stake in shares of Thermo Fisher Scientific by 2.7% in the 4th quarter. Callan Capital LLC now owns 773 shares of the medical research company’s stock valued at $402,000 after purchasing an additional 20 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the sale, the executive vice president now owns 23,167 shares in the company, valued at approximately $9,960,188.31. This trade represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total value of $5,166,700.00. Following the completion of the sale, the chief executive officer now owns 115,174 shares in the company, valued at $59,506,950.58. This trade represents a 7.99% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 14,075 shares of company stock worth $7,305,942 over the last 90 days. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO opened at $401.88 on Thursday. The stock has a fifty day simple moving average of $435.42 and a two-hundred day simple moving average of $502.00. Thermo Fisher Scientific Inc. has a 1-year low of $390.50 and a 1-year high of $627.88. The firm has a market cap of $151.71 billion, a price-to-earnings ratio of 24.31, a price-to-earnings-growth ratio of 2.99 and a beta of 0.82. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The business had revenue of $10.36 billion during the quarter, compared to analyst estimates of $10.23 billion. During the same period in the prior year, the company earned $5.11 earnings per share. Thermo Fisher Scientific’s revenue was up .2% compared to the same quarter last year. Analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $1.72 annualized dividend and a dividend yield of 0.43%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.09%.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Wednesday, May 21st. Barclays decreased their target price on Thermo Fisher Scientific from $620.00 to $475.00 and set an “equal weight” rating for the company in a research report on Thursday, April 10th. Raymond James reaffirmed an “outperform” rating and issued a $667.00 target price (up from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. Citigroup decreased their target price on Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Finally, Royal Bank of Canada decreased their target price on Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating for the company in a research report on Thursday, April 24th. Four investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average price target of $607.43.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.